Advantages of gadobenate dimeglumine-enhanced MR cholangiography in the diagnosis of post-liver transplant bile leakage

Greif, 1994, The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation, Ann Surg, 219, 40, 10.1097/00000658-199401000-00007 Król, 2011, Biliary complications after orthotopic liver transplantation: a 5-year experience, Transplant Proc, 10, 3035, 10.1016/j.transproceed.2011.08.071 Perrakis, 2010, Biliary tract complications after orthotopic liver transplantation: still the “Achilles heel”?, Transplant Proc, 12, 4154, 10.1016/j.transproceed.2010.09.045 Loperfido, 1998, Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study, Gastrointest Endosc, 7, 1, 10.1016/S0016-5107(98)70121-X Masci, 2001, Complications of diagnostic and therapeutic ERCP: a prospective multicenter study, Am J Gastroenterol, 2, 417, 10.1111/j.1572-0241.2001.03594.x Assaban, 2006, Mangafodipir trisodium-enhanced magnetic resonance cholangiography for detection of bile leaks, J Radiol, 1, 41, 10.1016/S0221-0363(06)73968-3 Frydrychowicz, 2012, Hepatobiliary MR imaging with gadolinium based contrast agents, J Magn Reson Imaging, 3, 492, 10.1002/jmri.22833 Seale, 2009, Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree, Radiographics, 10, 1725, 10.1148/rg.296095515 Davies, 2002, Pharmacokinetics and safety of gadobenate dimeglumine (Multihance) in subjects with impaired liver function, Invest Radiol, 5, 299, 10.1097/00004424-200205000-00008 Spinazzi, 1999, Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers, Acad Radiol, 5, 282, 10.1016/S1076-6332(99)80451-6 Shellock, 2006, Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance, Invest Radiol, 6, 500, 10.1097/01.rli.0000209661.99225.c2 Kirchin, 1998, Gadobenate dimeglumine (Gd-BOPTA). An overview, Invest Radiol, 11, 798, 10.1097/00004424-199811000-00003 Pirovano, 2000, Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions, AJR, 10, 1111, 10.2214/ajr.175.4.1751111 Schneider, 2003, Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison, Invest Radiol, 2, 85, 10.1097/00004424-200302000-00003 Cavagna, 1997, Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging, Invest Radiol, 12, 780, 10.1097/00004424-199712000-00009 Hamm, 1995, Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging, Radiology, 6, 785, 10.1148/radiology.195.3.7754011